| 0 (0%) | 10-14 18:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.9 | 1-year : | 12.8 |
| Resists | First : | 10.19 | Second : | 10.96 |
| Pivot price | 10  |
|||
| Supports | First : | 8.96 | Second : | 7.45 |
| MAs | MA(5) : | 9.4 |
MA(20) : | 10.02 |
| MA(100) : | 7.85 |
MA(250) : | 7.39 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 9.4 |
D(3) : | 11 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 11.03 | Low : | 4.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INFU ] has closed above bottom band by 3.3%. Bollinger Bands are 10.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.31 - 9.4 | 9.4 - 9.45 |
| Low: | 8.78 - 8.9 | 8.9 - 8.97 |
| Close: | 9.01 - 9.2 | 9.2 - 9.31 |
Fri, 10 Oct 2025
Sohail Masood: Home infusion pharmacy trailblazer - USC Today
Mon, 06 Oct 2025
Here's Why Momentum in InfuSystems Holdings (INFU) Should Keep going - Yahoo Finance
Mon, 29 Sep 2025
Update on Alert: Infusion Set Performance Issue from BD - fda.gov
Thu, 25 Sep 2025
Healthcare Service Provider InfuSystem Leadership to Present at ROTH Conference in New York - Stock Titan
Wed, 24 Sep 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial - Nature
Tue, 23 Sep 2025
Lactate IV infusion found to trick the body into releasing a hormone behind that post-workout brain boost - Frontiers
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 20 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 75.6 (%) |
| Shares Short | 161 (K) |
| Shares Short P.Month | 167 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.67 |
| Profit Margin | 3.6 % |
| Operating Margin | 10.4 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 9.3 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 3.73 |
| Sales Per Share | 6.84 |
| EBITDA (p.s.) | 1.19 |
| Qtrly Earnings Growth | 300 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | 38.08 |
| PEG Ratio | 0 |
| Price to Book value | 3.42 |
| Price to Sales | 1.33 |
| Price to Cash Flow | 7.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|